Global Opioid Induced Constipation drug market is estimated to grow with approx.7.08% CAGR during the year 2017 – 2025. The base year considered for the study is 2016 and the forecast period is 2017-2025. The important driver increasing growth in the Global Opioid Induced Constipation (OIC) drug Market is the increasing prescription of opioid in North America and Europe. Opioid-induced constipation market is expected to grow at an extraordinary growth rate over the forecasted time period.

GLOBAL OPIOID INDUCED CONSTIPATION DRUG MARKET FORECAST 2017-2025

Global Opioid Induced Constipation drug market by Drug Type (Methyl Naltrexone Bromide, Lubiprostone, Naloxegol, Naldemedine, Alvimopan, Dolcanatide, Elobixibat ) by Prescription Type (Prescribed Drugs, Over the Counter Drugs) & by Geography

Request free sample

Global Opioid Induced Constipation drug market is estimated to grow with approx.7.08% CAGR during the year 2017 – 2025. The base year considered for the study is 2016 and the forecast period is 2017-2025. The global OIC drug market is primarily driven by the following factors:

  • Rising use of opioid
  • Increasing geriatric population
  • Increasing opioid prescription in North America and Europe
  • Detection of safety threats
  • Easy availability of improved and effective OIC drugs

The important driver increasing growth in the Global Opioid Induced Constipation drug Market is the increasing prescription of opioid in North America and Europe. Opioid-induced constipation market is expected to grow at an extraordinary growth rate over the forecasted time period. An overwhelming growth is expected from the United States. Around 259 million prescriptions for opioids were prescribed by the doctors in the year 2012 in this region. Some of the commonly prescribed opioids are Percocet, Vicodin, and Codeine.

Over-the-counter (OTC) medicines are medicines that can be bought without a prescription from a doctor. Laxatives are a type of OTC medicine used to treat constipation. Many different kinds of OTC laxatives are available in the market. Some constipation medicines may also be called as stool softeners or fiber supplements. Constipation includes infrequent bowel movements with stools that are hard and sometimes painful to pass. Over-the-counter fiber products such as Dulcolax (brand name Metamucil), polycarbophil (FiberCon), methylcellulose (Citrucel) and Bisacodyl are usually the easily available choice for OIC. They enable the intestine to contract due to stimulation caused by the drug.

Side effects of OIC drugs and unawareness and ignorance among the patients are the major factors hindering the Opioid Induced Constipation drug market. Opioid induced constipation is a side effect of the opioids which are given as treatment for severe pain. The drugs prescribed to the patient, themselves have a large number of side effects due to which they are often avoided, and this acts as a major restraint for the market.

The Global Opioid Induced Constipation drug market segments include the drug type and the prescription type.

Drug types are as follows:

  • Methyl naltrexone Bromide
  • Lubiprostone
  • Naloxegol

Prescription types are as follows:

  • Prescribed
  • Over the Counter

The report scope is widely categorized on the basis of its drug types which include Methyl naltrexone Bromide, Lubiprostone, and Naloxegol. Moreover, the market revenue estimates and forecast includes only drugs and exclude the surgical method.

Geographically, the global opioid induced constipation drug market has been segmented on the basis of four major regions, which includes:

North America is anticipated to dominate the global OIC drugs market in the coming years. North America has two of the most developed nations in the world, namely the US and Canada, who have the most developed healthcare systems and medical devices industry in the world. Federal agencies and private firms equally participate in providing access to best medical facilities to the consumer. The region of North America has the highest number of patients suffering from constipation, and the condition was found in approximately 50% of the population. OIC condition is at an extreme level, and the increasing prevalence of this OIC has been observed in almost every American, seeking treatment at some point or other. Growing lifestyle oriented diseases, increase in healthcare spending and technological advancement in cardiology are the factors responsible for the growth of this market. On the other hand, Asia Pacific is expected to be the fastest growing region. Japan and China, in particular, are considered to be very promising countries for the drug market.

The OIC drug market is segmented based on the drug types which is further subdivided into Methyl naltrexone Bromide, Lubiprostone, and Naloxegol, and also on the basis of prescription types which is subdivided into prescribed drugs and over the counter drugs.

The major market players of the Global Opioid Induced Constipation drug market are:

  • IRONWOOD PHARMACEUTICALS INC
  • TAKEDA PHARMACEUTICAL
  • VALEANT PHARMACEUTICALS INTERNATIONAL
  • DAIICHI SANKYO CO LTD
  • SUCAMPO PHARMACEUTICALS
  • OTHERS

Company Profiles covers analysis of important players:

In January 2016, Ironwood Pharmaceuticals Inc entered into a collaboration with Bionomics Limited. According to this agreement, Ironwood will fund full-time equivalents for drug discovery activities performed by Bionomics.

In April 2017, Finch Therapeutics, a privately held microbiome engineering company, and Takeda Pharmaceutical Company Limited announced a global collaboration agreement to develop FIN-524 jointly. FIN-524 is a live biotherapeutic product in pre-clinical research. It is composed of cultured bacterial strains that have been linked to favorable clinical outcomes in studies of microbiota transplantation in IBD.

 Key Findings of the Global Opioid Induced Constipation drug market.

  • Rising use of opioid and increasing opioids prescription in North America and Europe is fueling growth in global Opioid Induced Constipation drug market.
  • North America is anticipated to account for the largest revenue share in 2016.
  • Over the counter, drug segment is the dominating market as doctor’s prescription is not required to buy the drugs
  • Increasing government support
  • Product launch is the key strategy adopted by the various market players of global opioid induced constipation drug market.
  • Lubiprostone is the major type of drug.
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
  4. MARKET OVERVIEW
    • MARKET DEFINITION
    • KEY MARKET INSIGHTS
    • ATTRACTIVE INVESTMENT SCENARIO
    • POSITIONING OF KEY OIC DRUGS MANUFACTURERS IN THE MARKET
    • MARKET DRIVERS
      • RISING USE OF OPIOID
      • INCREASING GERIATRIC POPULATION
      • INCREASING OPIOIDS PRESCRIPTION IN NORTH AMERICA AND EUROPE
      • EASY AVAILABILITY OF IMPROVED AND EFFECTIVE OIC DRUGS
    • RESTRAINTS
      • RESEARCH ON PAIN AND NEXT GENERATION ANALGESICS
      • SIDE EFFECTS OF OIC DRUGS
      • UNAWARENESS AND IGNORANCE AMONG PATIENTS
    • OPPORTUNITY
      • RISING DEMAND FOR OIC DRUGS FROM APAC MARKET
      • INCREASING USE OF OPIOIDS
    • CHALLENGES
      • LARGE NUMBER OF CONSIDERATIONS WHILE USING OPIOIDS
  1. GLOBAL OIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
    • OVERVIEW
      • METHYL NALTREXONE BROMIDE
      • LUBIPROSTONE
      • NALOXEGOL
    • PIPELINE DRUG ANALYSIS: PHASE 3: NALDEMEDINE (YEAR OF LAUNCH TO 2022 $ MILLION)
    • PIPELINE DRUG ANALYSIS: PHASE 2: ALVIMOPAN, DOLCANATIDE (QUALITATIVE INFORMATION)
    • PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH TO 2022 $ MILLION)
  2. GLOBAL OIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
    • PRESCRIBED DRUGS
      • BRANDED
      • GENERIC
    • OVER THE COUNTER DRUGS
  3. KEY ANALYTICS
    • PORTERS FIVE FORCE MODEL
      • INTENSITY OF COMPETITIVE RIVALRY
      • BARGAINING POWER OF SUPPLIERS
      • BARGAINING POWER OF BUYERS
      • THREAT OF SUBSTITUTE PRODUCTS
      • THREAT OF NEW ENTRANTS
    • VENDOR LANDSCAPE
    • OPPORTUNITY MATRIX
  4. GLOBAL OIC DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
    • NORTH AMERICA
      • US
      • CANADA
    • EUROPE
      • UK
      • GERMANY
      • REST OF THE EUROPE
    • ASIA PACIFIC
      • CHINA
      • JAPAN
      • REST OF ASIA PACIFIC
    • REST OF THE WORLD
      • MIDDLE EAST AND AFRICA
      • LATIN AMERICA
      • REST OF THE ROW
  1. COMPANY PROFILE
    • IRONWOOD PHARMACEUTICALS INC
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • DAIICHI SANKYO CO LTD
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • PFIZER
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • PROGENICS PHARMACEUTICALS INC
      • OVERVIEW
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • SHIONOGI & CO., LTD.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • ALLERGAN PLC
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • NEKTAR THERAPEUTICS
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • PURDUE PHARMA L.P.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • L.A. PHARMA AG
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
    • MUNDIPHARMA INTERNATIONAL LIMITED
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • ONO PHARMACEUTICAL CO., LTD.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • THERAVANCE BIOPHARMA INC
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • VALEANT PHARMACEUTICALS INTERNATIONAL
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • COSMO PHARMACEUTICALS SA
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • DAEWOONG PHARMACEUTICAL CO., LTD.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • B. FLEET COMPANY, INC.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS
    • SUCAMPO PHARMACEUTICALS
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • STRATEGIC MOVES
      • SCOT ANALYSIS

 

LIST OF TABLES

TABLE 1 GLOBAL OIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 2 PHARMACOLOGICAL APPROACHES TO TREAT OPIOID INDUCED CONSTIPATION

TABLE 3 LAXATIVES USED FOR OPIOID INDUCED CONSTIPATION

TABLE 4 SIDE EFFECTS OF USING LAXATIVES

TABLE 5 PATIENTS UNFIT FOR INTAKE OF OPIOIDS

TABLE 6 GLOBAL OIC DRUG MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)

TABLE 7 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)

TABLE 8 GLOBAL METHYL NALTREXONE BROMIDE OIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($MILLION)

TABLE 9 PRODUCT PROFILE (LUBIPROSTONE)

TABLE 10 GLOBAL LUBIPROSTONE OIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($MILLION)

TABLE 11 PRODUCT PROFILE (NALOXEGOL)

TABLE 12 GLOBAL NALOXEGOL OIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($MILLION)

TABLE 13 PIPELINE PRODUCT PROFILE (NALDEMEDINE)

TABLE 14 PIPELINE PRODUCT PROFILE (ALVIMOPAN, DOLCANATIDE)

TABLE 15 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)

TABLE 16 GLOBAL OIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

TABLE 17 PRODUCT PROFILE (LUBIPROSTONE)

TABLE 18 GLOBAL PRESCRIBED OIC DRUGS MARKET 2017-2025($ MILLION)

TABLE 19 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)

TABLE 20 PRODUCT PROFILE (METAMUCIL)

TABLE 21 PRODUCT PROFILE (BISACODYL)

TABLE 22 GLOBAL OVER THE COUNTER OIC DRUG BY GEOGRAPHY 2017-2025($ MILLION)

TABLE 23 GLOBAL OIC DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 24 NORTH AMERICA OIC DRUGS MARKET BY COUNTRY, 2017-2025($ MILLION)

TABLE 25 EUROPE OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)

TABLE 26 ASIA PACIFIC OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)

TABLE 27 REST OF WORLD OIC DRUG MARKET 2017-2025 ($ MILLION)

LIST OF FIGURES

FIGURE 1 GLOBAL OIC DRUGS MARKET 2017-2025 ($ MILLION)

FIGURE 2 GLOBAL OIC DRUG MARKET BY DRUG TYPE 2016 AND 2025 (%)

FIGURE 3 GLOBAL OIC DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)

FIGURE 4 INCREASING NUMBER OF OPIOID PRESCRIPTION ($ MILLION)

FIGURE 5 REASONS FOR THE GROWTH OF OPIOID MARKET.

FIGURE 6 THERAPEUTIC OPIOID USE IN US (G/100,000 POPULATION)

FIGURE 7 COMMON SIDE EFFECTS OF MOVANTIK

FIGURE 8 MAJOR USAGE OF OPIOIDS

FIGURE 9 CONSIDERATIONS TAKEN WHILE THE OPIOID USAGE

FIGURE 10 GLOBAL METHYL NALTREXONE BROMIDE OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 11 GLOBAL LUBIPROSTONE OIC DRUG MARKET 2017-2025 ($MILLION)

FIGURE 12 GLOBAL NALOXEGOL OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 13 GLOBAL PRESCRIBED OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 14 GLOBAL PRESCRIBED BRANDED OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 15 GLOBAL PRESCRIBED GENERIC OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 16 GLOBAL OVER THE COUNTER OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 17 NORTH AMERICA OIC DRUGS MARKET 2017-2025 ($ MILLION)

FIGURE 18 US OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 19 CANADA OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 20 NUMBER OF PRESCRIPTIONS DISPENSED FOR OPIOIDS

FIGURE 21 EUROPE OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 22 UK OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 23 GERMANY OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 24 REST OF EUROPE OIC DRUG MARKET 2017-2025($ MILLION)

FIGURE 25 ASIA PACIFIC OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 26 CHINA OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 27 PHARMACEUTICALS MARKET SALES ACROSS THE GLOBE (%)

FIGURE 28 JAPAN OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 29 REST OF APAC OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 30 MIDDLE EAST AND AFRICA OIC DRUG MARKET 2017-2025($ MILLION)

FIGURE 31 LATIN AMERICA OIC DRUG MARKET 2017-2025($ MILLION)

FIGURE 32 REST OF ROW OIC DRUG MARKET 2017-2025($ MILLION)

  1. GLOBAL OIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
    • OVERVIEW
      • METHYL NALTREXONE BROMIDE
      • LUBIPROSTONE
      • NALOXEGOL
    • PIPELINE DRUG ANALYSIS: PHASE 3: NALDEMEDINE (YEAR OF LAUNCH TO 2022 $ MILLION)
    • PIPELINE DRUG ANALYSIS: PHASE 2: ALVIMOPAN, DOLCANATIDE (QUALITATIVE INFORMATION)
    • PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH TO 2022 $ MILLION)
  2. GLOBAL OIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
    • PRESCRIBED DRUGS
      • BRANDED
      • GENERIC
    • OVER THE COUNTER DRUGS
  3. GLOBAL OIC DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
    • NORTH AMERICA
      • US
      • CANADA
    • EUROPE
      • UK
      • GERMANY
      • REST OF THE EUROPE
    • ASIA PACIFIC
      • CHINA
      • JAPAN
      • REST OF ASIA PACIFIC
    • REST OF THE WORLD
      • MIDDLE EAST AND AFRICA
      • LATIN AMERICA
      • REST OF THE ROW

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Choose License Type